Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Lipopolysaccharides: Strategies for Treating Endotoxin-Induced Health Issues

Medically reviewed by 
Lipopolysaccharides: Strategies for Treating Endotoxin-Induced Health Issues

Lipopolysaccharides (LPS), or endotoxins, are components of the outer membrane of Gram-negative bacteria that can provoke significant immune responses when they enter the human body, leading to various health issues. 

This article discusses the health impacts of LPS exposure and strategies for treating conditions caused by endotoxin exposure, encompassing both medical and lifestyle interventions. 


What Are Lipopolysaccharides (LPS)? 

Lipopolysaccharides (LPS) are components of the outer cell membrane of gram-negative bacteria. The gram-negative bacterial cell membrane consists of an inner and outer membrane. LPS molecules are considered bacterial toxins. When they enter the body during an infection they can trigger a severe immune reaction.

LPS are composed of three main parts, Lipid A, which is the most virulent factor, O-antigen, and a hydrophilic core. The O-antigen varies between different bacterial strains and provides antigenic specificity aiding in the diagnosis of active infection. 

How Do Lipopolysaccharides (LPS) Contribute to Diseases?

LPS enters the blood through a bacterial infection and leads to a series of immune reactions.

  1. Secretion of several pro-inflammatory cytokines through activation of toll-like receptors (TLRs).
  2. After the TLRs recognize the LPS it causes the release of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), IL-6, and IL-8
  3. Once the cytokines are released into the bloodstream, they cause widespread inflammation and activation of reactive oxygen species (ROS), which produces an overwhelming immune response and oxidative stress in the body. 
  4. The severity of the immune response can lead to cell damage with potentially lethal effects. 

The following are common health issues associated with high levels of endotoxin exposure:

How to Treat Endotoxin-Induced Conditions

The medical approach to treating endotoxin illness primarily focuses on using targeted antibiotics to eradicate the underlying bacterial infection alongside supportive therapies to manage inflammation and prevent complications.

The Medical Approach to Treating Endotoxin-Induced Conditions


Gram-negative bacteria that contain LPS are some of the hardest infections to treat due to antibiotic resistance. Conventional antibiotic therapy for gram-negative bacteria effectively kills the bacteria but does not effectively neutralize LPS. 

Among antibiotics currently being used for endotoxin-induced conditions are beta-lactam antibiotics such as carbapenems, which have shown a reduced risk of sepsis. For less severe infections caused by gram-negative bacteria, the use of fluoroquinolones and aminoglycoside antibiotics has shown efficacy if started promptly. 

Endotoxin Neutralization: 

An alternative strategy to managing endotoxin-related illness is through neutralizing the LPS. This can be accomplished with Polymyxin B, an antibiotic that can kill gram-negative bacteria and bind circulating endotoxin without causing systemic toxicity. 

Polymixin drugs target the bacterial cell membrane causing bacterial lethality, however, they can cause nephrotoxicity and neurotoxicity. For this reason, polymyxin use is limited and only reserved as a last-line treatment for endotoxin-related illness. 

Anti-inflammatory Medications: 

Endotexmia can cause widespread inflammation in the body causing serious complications. While antibiotics are necessary for treatment, incorporating medications to reduce inflammation is crucial. 

  • Anti-inflammatory medications such as NSAIDs and corticosteroids can help diminish the inflammation caused by endotoxin illness. 
  • Low-dose hydrocortisone is effective in reducing cytokine production and systemic inflammation caused by endotoxemia (2). 

The Complementary Approach to Support Treatments of Endotoxin-Induced Conditions

Probiotics and Gut Health: 

Endotexmia develops when endotoxins such as LPS reach the bloodstream due to increased intestinal permeability. Intestinal permeability can allow harmful microorganisms and toxins to enter the bloodstream. Maintaining a healthy microbiome and implementing probiotics can help strengthen the gut wall, reducing endotoxin production and the chance of endotoxins reaching the bloodstream. 

Spore-based probiotics such as Bacillus indicus, Bacillus subtilis, and Bacillus coagulans reduce symptoms of leaky gut syndrome. These spore-based probiotics are associated with a 45% reduction in endotoxin levels in the blood. Lactobacillus probiotics are also effective in maintaining a healthy gut wall by enhancing goblet cells, a mechanism used to enhance barrier function (1). 

Implementing nutraceuticals such as L-glutamine helps regulate tight junctions in the gut which reduces intestinal permeability and reduces intestinal endotoxin levels. Polyphenols such as quercetin, curcumin, and resveratrol also enhance tight junction integrity, improving intestinal permeability.

Dietary Modifications: 

Making dietary changes to reduce processed foods and incorporating anti-inflammatory foods can help heal leaky gut and aid in preventing and treating endotoxin-related illnesses. The following are dietary recommendations to reduce inflammation and heal leaky gut:

  • Decrease intake of processed carbohydrates such as sweetened beverages, bread, snack foods, and alcohol, as these foods are associated with a decreased microbiome diversity
  • Incorporate foods high in fiber, such as fruit and vegetables
  • Including coffee, tea, and red wine in moderation helps increase beneficial bifidobacteria in the gut
  • Decrease intake of fermentable oligosaccharides (FODMAPs) such as fructans, sorbitol, and xylitol as they lead to intestinal inflammation and a weakened gut wall.
  • Increasing intake of yogurt can help protect the intestinal epithelium
  • Medicinal mushrooms such as Chaga can modulate gut microbiota and decrease intestinal inflammation

Hydration and Detoxification: 

Incorporating detoxification strategies can assist in flushing out bacterial toxins from the body. 

  • Focus on activities that make you sweat, such as physical exercise and sauna use, to help decrease total toxin load (5)
  • Increasing hydration helps support the kidneys in filtering out bacterial toxins and waste products from the blood
  • Supporting liver detox with berberine, milk thistle, and glutathione (41)
  • Castor oil packs over the liver decrease inflammation and support detoxification

Innovative Research and Emerging Treatments

Toll-like receptor 4 (TLR4) is the main signaling pathway in endotoxin-related illness. Modulation of the TLR4 pathway through natural and synthetic sources is an emerging strategy to reduce bacterial endotoxin disease. 

  • Berberine blocks the TLR4 pathway and reduces NF-Kb signaling, leading to decreased systemic inflammation.
  • Humulus lupulus (Hops) has shown anti-inflammatory effects by blocking TLR4 activation
  • Sulforaphane, naturally found in cruciferous vegetables, blocks LPS interaction with TLR4 receptors
  • Synthetic compounds such as resatorvid and eritoran block TLR4 activity by mimicking the lipid A portion of LPS

Gene Therapy and Molecular Techniques

Gene therapy and molecular techniques for endotoxin-related illnesses are an emerging area of research that aims to address the underlying mechanisms of immune response and inflammation triggered by LPS. Anti-microbial peptides (AMPs) such as cathelicidin, have shown promising efficacy in the neutralization of gram-negative bacteria (42). 


Key Takeaways

  • Lipopolysaccharides (LPS), also known as endotoxins, are a major component of gram-negative bacteria and trigger a severe immune response and systemic inflammation
  • Endotoxins can cause a wide range of systemic health issues, from mild inflammation, fever, poor gut health, chronic pain/fatigue, cardiovascular disorders, and autoimmunity.
  • Incorporating dietary, nutraceutical, and detoxification strategies can greatly help decrease inflammation in endotoxin-related illnesses.
  • Emerging research in herbal medicine, pharmaceuticals, and peptide therapy shows promising therapeutic potential in regulating inflammation caused by LPS immune activation.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.
  1. Aleman, R. S., Moncada, M., & Aryana, K. J. (2023). Leaky Gut and the Ingredients That Help Treat It: A Review. Molecules, 28(2), 619.
  2. Alvarez, S. M., Maria Katsamanis Karavidas, Coyle, S. M., Lu, S.-E., Macor, M., Oikawa, L. O., Lehrer, P. M., Calvano, S. E., & Lowry, S. F. (2007). Low-dose steroid altersin vivoendotoxin-induced systemic inflammation but does not influence autonomic dysfunction. Journal of Endotoxin Research, 13(6), 358–368.
  3. Aminoglycosides - Infectious Diseases. (n.d.). Merck Manuals Professional Edition.
  4. Bertanga, B. (2024, January 4). Understanding the Potential Benefits of Milk Thistle for Fatty Liver. Rupa Health.
  5. Bonakdar, R., Sweeney, M., Dalhoumi, S., Adair, V., Garvey, C., Hodge, T., Herrala, L., Barbee, A., Case, C., Kearney, J., Ma, C., Smith, K., Hwang, J., Robert, N., Bonakdar, A., Scripps, C., Ma, S., & Living. (2020). 16 Bonakdar-Detoxification Enhanced Lifestyle Intervention. Integrative Medicine •, 19(5).
  6. Brandenburg, K., Schromm, A. B., Weindl, G., Heinbockel, L., Correa, W., Mauss, K., Martinez de Tejada, G., & Garidel, P. (2020). An update on endotoxin neutralization strategies in Gram-negative bacterial infections. Expert Review of Anti-Infective Therapy, 19(4), 495–517.
  7. Carbapenems - Infectious Diseases. (n.d.). Merck Manuals Professional Edition.
  8. Christie, J. (2022, August 15). It’s Time To Start Treating Coffee Like A Health Food. Rupa Health.
  9. Cloyd, J. (2023a, February 28). A Functional Medicine Protocol for Leaky Gut Syndrome. Rupa Health.
  10. Cloyd, J. (2023b, April 5). Treatment of Antibiotic Resistance Through Functional Medicine. Rupa Health.
  11. Cloyd, J. (2023c, May 10). Unlocking the Secrets of Lactobacillus: A Comprehensive Guide to Testing Patient Levels and Deciphering High and Low Levels. Rupa Health.
  12. Cloyd, J. (2023d, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health.
  13. Cloyd, J. (2023e, July 7). Integrative Approaches to Reducing Toxin Exposure in Everyday Life. Rupa Health.
  14. Cloyd, J. (2023f, November 8). Quercetin 101: Getting to Know This Powerful Substance and How You Can Use it For Your Health. Rupa Health.
  15. Cloyd, J. (2023g, December 5). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health.
  16. Cloyd, J. (2024, January 11). Integrating Resveratrol for Improved Insulin Sensitivity and Endocrine Health. Rupa Health.
  17. Cloyd, K. (2023, December 20). Interpreting Oxidative Stress Markers. Rupa Health.
  18. Connor, V. (2022, October 11). 6 Complementary and Alternative Therapies for Chronic Fatigue Syndrome. Rupa Health.
  19. Daglis, S. (2024, April 16). Berberine 101: What It Is, Benefits, and Side Effects. Rupa Health.
  20. Dao, D.-P. D., & Le, P. H. (2020). Histology, Goblet Cells. PubMed; StatPearls Publishing.
  21. DePorto, T. (2023, January 31). Glutathione Health Benefits: The Master Antioxidant. Rupa Health.
  22. Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022). Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Frontiers in Immunology, 13.
  23. DynaMedex. (n.d.). Retrieved May 19, 2024, from
  24. Farhana, A., & Khan, Y. S. (2020). Biochemistry, Lipopolysaccharide. PubMed; StatPearls Publishing.
  25. Fluoroquinolones - Infectious Diseases. (n.d.). Merck Manuals Professional Edition.
  26. Garrison, K. (2024, April 30). How Castor Oil Can Complement Your Anti-Inflammatory Treatment Plan. Rupa Health.
  27. Glutamine. (n.d.). Rupa Health. Retrieved May 19, 2024, from
  28. Greenan, S. (2021, November 18). How To Do A Low FODMAP Elimination Diet. Rupa Health.
  29. Hills, R. D., Pontefract, B. A., Mishcon, H. R., Black, C. A., Sutton, S. C., & Theberge, C. R. (2019). Gut Microbiome: Profound Implications for Diet and Disease. Nutrients, 11(7), 1613.
  30. Interleukin 8. (n.d.). Rupa Health.
  31. Jung, F., Staltner, R., Baumann, A., Burger, K., Halilbasic, E., Hellerbrand, C., & Bergheim, I. (2022). A Xanthohumol-Rich Hop Extract Diminishes Endotoxin-Induced Activation of TLR4 Signaling in Human Peripheral Blood Mononuclear Cells: A Study in Healthy Women. International Journal of Molecular Sciences, 23(20), 12702.
  32. Khakham MBA, NMD , C. (2023, October 9). Gut Health and Medicinal Mushrooms: Exploring the Gut-Immune Connection. Rupa Health.
  33. Khakham, C. (2023a, March 7). Top Medical Evidence Supporting Curcumin’s Health Benefits. Rupa Health.
  34. Khakham, C. (2023b, May 23). A Comprehensive Review of IBS-D: Differential Diagnosis, Specialty Testing, and Integrative Treatment Options. Rupa Health.
  35. Khakham, C. (2023c, May 23). An integrative medicine approach to alzheimer’s disease: Testing, nutrition, and supplements. Rupa Health.
  36. Koo, J. E., Park, Z.-Y., Kim, N. D., & Lee, J. Y. (2013). Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2. Biochemical and Biophysical Research Communications, 434(3), 600–605.
  37. Kresge, K. (2022, April 15). 4 Possible Causes Of Parkinson’s And 5 Things That Make It Worse. Rupa Health.
  38. Kuzmich, N., Sivak, K., Chubarev, V., Porozov, Y., Savateeva-Lyubimova, T., & Peri, F. (2017). TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis. Vaccines, 5(4), 34.
  39. Maholy, N. (2023, June 29). The Role of Probiotics and Prebiotics in Gut Health: An Integrative Perspective. Rupa Health.
  40. McFarlin, B. K., Henning, A. L., Bowman, E. M., Gary, M. A., & Carbajal, K. M. (2017). Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World Journal of Gastrointestinal Pathophysiology, 8(3), 117.
  41. Methiye Mancak. (2023). Evidence-based herbal treatments in liver diseases. Hepatology Forum/Hepatology Forum (Online), 50–60.
  42. Mohammad, S., & Thiemermann, C. (2021). Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Frontiers in Immunology, 11.
  43. Mohapatra, S. S., Dwibedy, S. K., & Padhy, I. (2021). Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions. Journal of Biosciences, 46(3).
  44. Molteni, M., Bosi, A., & Rossetti, C. (2018). Natural Products with Toll-Like Receptor 4 Antagonist Activity. International Journal of Inflammation, 2018, 1–9.
  45. Neibling, K. (2023, April 26). Complementary and Integrative Medicine Treatments for Hypertension and Cardiovascular Disease. Rupa Health.
  46. Neilburg, K. (2023, April 17). An Integrative Medicine Approach to ALS Treatment. Rupa Health.
  47. Page, M. J., Kell, D. B., & Pretorius, E. (2022). The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation. Chronic Stress, 6, 24705470221076390.
  48. Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E. (2020). Interleukin-6 in Rheumatoid Arthritis. International Journal of Molecular Sciences, 21(15), 5238.
  49. Perera MD, H. (2024, April 11). The Ultimate Fiber Foods List: Boost Your Health with High-Fiber Choices. Rupa Health.
  50. Preston, J. (2023, September 22). Addressing Inflammation in Chronic Diseases: A Functional Medicine Perspective. Rupa Health.
  51. Preston, J. (2024, February 1). Integrative Approach to Chronic Inflammatory Response Syndrome (CIRS). Rupa Health.
  52. Stanford, J. (2024, February 19). The Hidden Perils of Refined Carbohydrates: What Every Healthcare Professional Needs to Know. Rupa Health.
  53. Tani, T., Shimizu, T., Tani, M., Shoji, H., & Endo, Y. (2019). Anti-endotoxin Properties of Polymyxin B-immobilized Fibers. Advances in Experimental Medicine and Biology, 1145, 321–341.
  54. Tumor Necrosis Factor Alpha. (n.d.). Rupa Health. Retrieved May 19, 2024, from
  55. van Harten, R., van Woudenbergh, E., van Dijk, A., & Haagsman, H. (2018). Cathelicidins: Immunomodulatory Antimicrobials. Vaccines, 6(3), 63.
  56. Villegas, M. V., & Lyon, S. (2018). Gram-negative infections: evolving treatments with expanding options. Future Science OA, 4(9), FSO339.
  57. Wassenaar, T. M., & Zimmermann, K. (2018). Lipopolysaccharides in food, food supplements, and probiotics: should we be worried? European Journal of Microbiology and Immunology, 8(3), 63–69.
  58. Weinberg, J. (2023a, January 11). How To Test Your Patients For Metabolic Syndrome. Rupa Health.
  59. Weinberg, J. (2023b, December 26). The Power of Polyphenols: Functional Medicine’s Antioxidant Superstars. Rupa Health.
  60. Yoshimura, H. (2023, December 18). Exploring the Connection Between Chronic Pain and Emotional Wellbeing in Functional Medicine. Rupa Health.
  61. Yoshimura, H. (2024, April 8). Evidence-Based Review: The Role of Anti-Inflammatory Foods. Rupa Health.
  62. Yusra Habib Khan, Aroosa Liaqat, Tauqeer Hussain Mallhi, Abid, A., Nasser Hadal Alotaibi, & Khan, A. (2021). Bacterial Endotoxins and Neurological Disorders: From Exposure to Therapeutic Interventions. Emerging Contaminants and Associated Treatment Technologies, 49–67.
  63. Zhang, J.-M., & An, J. (2007). Cytokines, Inflammation, and Pain. International Anesthesiology Clinics, 45(2), 27–37.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.